Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia

Alan H. Shih, Stephen S. Chung, Emily K. Dolezal, Su Jiang Zhang, Omar I. Abdel-Wahab, Christopher Y. Park, Stephen D Nimer, Ross L. Levine, Virginia M. Klimek

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia. Large-scale mutation profiling efforts in de novo myelodysplastic syndromes have identified mutations that correlate with clinical features, but such mutations have not been investigated in therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Genomic DNA from 38 patient samples were subjected to high throughput polymerase chain reaction and sequenced for TP53, TET2, DNMT3A, ASXL1, IDH1, IDH2, EZH2, EED, SUZ12, RBBP4, SRSF2, U2AF35, and SF3B1. We identified somatic mutations in 16 of 38 (42%) patients. TP53 mutations were the most common lesion, detected in 8 of 38 (21%) patients, followed by TET2 in 4 of 38 (10.5%). Cases with a TP53 mutation or loss of the TP53 locus had a worse overall survival compared to those with wild-type TP53 (8.8 vs. 37.4 months; P=0.0035).

Original languageEnglish
Pages (from-to)908-912
Number of pages5
JournalHaematologica
Volume98
Issue number6
DOIs
StatePublished - Jun 6 2013
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Mutation
Therapeutics
Polymerase Chain Reaction
Survival
DNA

ASJC Scopus subject areas

  • Hematology

Cite this

Shih, A. H., Chung, S. S., Dolezal, E. K., Zhang, S. J., Abdel-Wahab, O. I., Park, C. Y., ... Klimek, V. M. (2013). Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica, 98(6), 908-912. https://doi.org/10.3324/haematol.2012.076729

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. / Shih, Alan H.; Chung, Stephen S.; Dolezal, Emily K.; Zhang, Su Jiang; Abdel-Wahab, Omar I.; Park, Christopher Y.; Nimer, Stephen D; Levine, Ross L.; Klimek, Virginia M.

In: Haematologica, Vol. 98, No. 6, 06.06.2013, p. 908-912.

Research output: Contribution to journalArticle

Shih, AH, Chung, SS, Dolezal, EK, Zhang, SJ, Abdel-Wahab, OI, Park, CY, Nimer, SD, Levine, RL & Klimek, VM 2013, 'Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia', Haematologica, vol. 98, no. 6, pp. 908-912. https://doi.org/10.3324/haematol.2012.076729
Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica. 2013 Jun 6;98(6):908-912. https://doi.org/10.3324/haematol.2012.076729
Shih, Alan H. ; Chung, Stephen S. ; Dolezal, Emily K. ; Zhang, Su Jiang ; Abdel-Wahab, Omar I. ; Park, Christopher Y. ; Nimer, Stephen D ; Levine, Ross L. ; Klimek, Virginia M. / Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. In: Haematologica. 2013 ; Vol. 98, No. 6. pp. 908-912.
@article{3c8a7cebcecc43ae9fef1f3b3b64f4a3,
title = "Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia",
abstract = "Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia. Large-scale mutation profiling efforts in de novo myelodysplastic syndromes have identified mutations that correlate with clinical features, but such mutations have not been investigated in therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Genomic DNA from 38 patient samples were subjected to high throughput polymerase chain reaction and sequenced for TP53, TET2, DNMT3A, ASXL1, IDH1, IDH2, EZH2, EED, SUZ12, RBBP4, SRSF2, U2AF35, and SF3B1. We identified somatic mutations in 16 of 38 (42{\%}) patients. TP53 mutations were the most common lesion, detected in 8 of 38 (21{\%}) patients, followed by TET2 in 4 of 38 (10.5{\%}). Cases with a TP53 mutation or loss of the TP53 locus had a worse overall survival compared to those with wild-type TP53 (8.8 vs. 37.4 months; P=0.0035).",
author = "Shih, {Alan H.} and Chung, {Stephen S.} and Dolezal, {Emily K.} and Zhang, {Su Jiang} and Abdel-Wahab, {Omar I.} and Park, {Christopher Y.} and Nimer, {Stephen D} and Levine, {Ross L.} and Klimek, {Virginia M.}",
year = "2013",
month = "6",
day = "6",
doi = "10.3324/haematol.2012.076729",
language = "English",
volume = "98",
pages = "908--912",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "6",

}

TY - JOUR

T1 - Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia

AU - Shih, Alan H.

AU - Chung, Stephen S.

AU - Dolezal, Emily K.

AU - Zhang, Su Jiang

AU - Abdel-Wahab, Omar I.

AU - Park, Christopher Y.

AU - Nimer, Stephen D

AU - Levine, Ross L.

AU - Klimek, Virginia M.

PY - 2013/6/6

Y1 - 2013/6/6

N2 - Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia. Large-scale mutation profiling efforts in de novo myelodysplastic syndromes have identified mutations that correlate with clinical features, but such mutations have not been investigated in therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Genomic DNA from 38 patient samples were subjected to high throughput polymerase chain reaction and sequenced for TP53, TET2, DNMT3A, ASXL1, IDH1, IDH2, EZH2, EED, SUZ12, RBBP4, SRSF2, U2AF35, and SF3B1. We identified somatic mutations in 16 of 38 (42%) patients. TP53 mutations were the most common lesion, detected in 8 of 38 (21%) patients, followed by TET2 in 4 of 38 (10.5%). Cases with a TP53 mutation or loss of the TP53 locus had a worse overall survival compared to those with wild-type TP53 (8.8 vs. 37.4 months; P=0.0035).

AB - Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia. Large-scale mutation profiling efforts in de novo myelodysplastic syndromes have identified mutations that correlate with clinical features, but such mutations have not been investigated in therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Genomic DNA from 38 patient samples were subjected to high throughput polymerase chain reaction and sequenced for TP53, TET2, DNMT3A, ASXL1, IDH1, IDH2, EZH2, EED, SUZ12, RBBP4, SRSF2, U2AF35, and SF3B1. We identified somatic mutations in 16 of 38 (42%) patients. TP53 mutations were the most common lesion, detected in 8 of 38 (21%) patients, followed by TET2 in 4 of 38 (10.5%). Cases with a TP53 mutation or loss of the TP53 locus had a worse overall survival compared to those with wild-type TP53 (8.8 vs. 37.4 months; P=0.0035).

UR - http://www.scopus.com/inward/record.url?scp=84878446656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878446656&partnerID=8YFLogxK

U2 - 10.3324/haematol.2012.076729

DO - 10.3324/haematol.2012.076729

M3 - Article

C2 - 23349305

AN - SCOPUS:84878446656

VL - 98

SP - 908

EP - 912

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -